Breaking News

AstraZeneca to Invest $2.5B in New Global R&D Center in Beijing

Investment includes agreements with Harbour BioMed, Syneron Bio and BioKangtai
.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: AstraZeneca

AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R&D center together with major research and manufacturing agreements in China. This investment over the next five years is part of a strategic partnership with the Beijing Municipal Government and the Beijing Economic-Technological Development Area Administrative Office and includes agreements with three biotechs; Harbour BioMed, Syneron Bio, and BioKangtai, and follows the recent Fibrogen announcement. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters